Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Developers Ask For Flexible Combinations In Co-Development Regulation

Executive Summary

Drug makers responding to FDA's draft guidance on co-development of novel drugs to be used in combination asked the agency to loosen up the boundaries on what kinds of products can be combined, particularly in light of the requirement that the products be aimed only at serious and life-threatening diseases for which there are no satisfactory alternatives.

You may also be interested in...



Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions

In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.

Bill Proposes Offering Exclusivity For Novel Drug Co-Development

Bill proposes six months’ extra marketing exclusivity to spur development of combinations of investigational drugs for serious diseases. Setting aside prospects for passage in an election season, the question is whether that will be enough to get pharma to buy into a risky development space and pioneer a new business model.

Will Progression-Free Survival Cut It In Brave New Melanoma World?

The changing landscape for melanoma drugs raises questions about the appropriateness of overall survival as a trial endpoint and the ethics of using old drugs like the chemotherapy dacarbazine as “standard of care” comparators in pivotal studies.

Related Content

Topics

UsernamePublicRestriction

Register

PS053138

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel